News | October 14, 2014

Infraredx Receives Regulatory Approval of TVC Imaging System in Japan

Infraredx TVC Imaging System Receives Regulatory Approval Japan

October 14, 2014 — Infraredx Inc. announced that its dual-modality intravascular imaging technology, TVC Imaging System, and its TVC Insight Catheter received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW). The TVC System makes it possible to determine the structure and chemical composition of the coronary plaques that complicate stenting, and are associated with heart attacks. The TVC Imaging System console and catheter will be exclusively distributed by Goodman, a subsidiary of Osaka-based Nipro Corp., which has extensive experience commercializing IVUS and other imaging technologies in Japan.

The TVC Imaging System integrates near-infrared spectroscopy (NIRS) to detect lipid-core plaques and enhanced intravascular ultrasound (IVUS) to visualize vessel structure, including the presence of plaques and the degree of stenosis (narrowing) due to plaque build-up. Lipid core plaque is a fatty coronary artery plaque associated with most heart attacks. The TVC Imaging System can identify plaques suspected to be vulnerable to rupture, which can cause a heart attack.

“The approval to market the TVC Imaging System in Japan marks an important milestone in our Asia-Pacific commercial expansion strategy, and we thank our partner Nipro for their instrumental role in advancing our regulatory and commercialization efforts in Japan,” said Don Southard, president and chief executive officer of Infraredx. “By combining NIRS and IVUS, two proven intravascular imaging modalities, the TVC Imaging System has the potential to add tremendous clinical value in the Japanese market, where the use of intravascular imaging during interventional coronary procedures is the standard of care.”

[More than 200,000 IVUS procedures were performed in Japan in 2014, and the country makes up 50 percent of the worldwide intravascular imaging market. The use of IVUS to guide percutaneous coronary intervention (PCI) is the standard of care in Japan, with use in more than 80 percent of all procedures.] While IVUS can reveal the structure of a vessel and the presence of plaque, it is not the optimal method to determine if the plaque contains a cholesterol rich lipid core. The TVC Imaging System is the only commercially available device approved in both the United States and Europe, and now Japan, to visualize both vessel structure and provide lipid core data.

“Approval and introduction of the advanced TVC Imaging System into Japan is welcome news for Japanese interventional cardiologists,” stated Dr. Takashi Akasaka, professor of medicine at Wakayama Medical University. “In Japan, cardiologists’ use of IVUS to guide percutaneous coronary interventions is standard practice, and integration of NIRS lipid core data with grayscale IVUS will provide a more comprehensive view of vessel structure, degree of stenosis and plaque composition. This combined data will enable physicians to make more informed treatment decisions and provide more effective patient management.”

Infraredx entered a partnership with Nipro last August and received an initial $25 million equity investment. Goodman, now a partially owned subsidiary of Nipro, has a successful history in the cardiovascular market as a distributor, establishing IVUS system market leadership for Boston Scientific and later for Volcano Corp. in Japan.

For more information: www.infraredx.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init